NCT01585649已完成1 期
Multicenter, Open-label Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100µg/kg XM22 in 21 Children With Ewing Family of Tumors or Rhabdomyosarcoma
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Merckle GmbH
- 入组人数
- 21
- 试验地点
- 18
- 主要终点
- PK: Area under the curve, Maximum observed serum concentration (Cmax), Rate constant associated with terminal phase, Mean Residence Time, Time to reach Cmax, and Apparent volume of distribution during terminal phase after non-intravenous administration
研究概览
简要总结
This is a Phase I, open label study aimed at assessing the pharmacokinetics, pharmacodynamics, the efficacy, safety, and tolerability of a single injection of XM22 in children with Ewing family of tumors or rhabdomyosarcoma scheduled to receive chemotherapy (CTX)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female children and adolescents aged 2 to <18 years
- •Written informed consent provided by parent(s)/legal representative(s) of the pediatric patient and patient's assent if appropriate
- •Able to understand and/or follow study instructions alone or with parental assistance
- •Diagnosed with the Ewing family of tumors or Rhabdomyosarcoma
- •Scheduled to receive 1 of the following CTX regimens (inpatient or outpatient)
- •For the Ewing family of tumors:
- •vincristine/ifosfamide/doxorubicin/etoposide (VIDE); with concomitant sodium 2-mercaptoethane sulfonate (MESNA) according to local standards
- •vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide (VDC/IE); with concomitant MESNA treatment according to local standards
- •For rhabdomyosarcoma:
- •vincristine/actinomycin/cyclophosphamide (VAC)
- •vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide (VDC/IE); with concomitant MESNA treatment according to local standards
- •Chemotherapy-naïve
- •Body weight ≥15 kg
- •White blood cell (WBC) count >2.5 x 109/L, absolute neutrophil count (ANC) ≥1.5 x 109/L, and platelet count ≥100 x 109/L (at screening and prior to CTX)
- •For patients aged ≥12 years, Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (See Appendix A.)
- •Fertile patients (male or female) must use highly reliable contraceptive measures (i.e. two of the following: oral contraception, implants, injections, barrier contraception, and intrauterine device, or vasectomized/sterilized partners, or sexual abstinence). For purposes of this study, a fertile female patient is any female patient who has experienced menarche and who has not undergone tubal ligation.
- •Female patients who have attained menarche must have a negative urine pregnancy test at the screening visit.
排除标准
- •Previous exposure to filgrastim, pegfilgrastim or lenograstim or other G-CSFs in clinical development within 6 months prior to the XM22 administration
- •Known hypersensitivity to filgrastim, pegfilgrastim or lenograstim or any other G-CSF in clinical development
- •History of congenital neutropenia or cyclic neutropenia
- •Any illness or condition that in the opinion of the Investigator may affect the safety of the patient or the evaluation of any study endpoint
- •Pregnant or nursing women
- •Fertile patients who do not agree to use highly reliable contraceptive measures during the entire duration of the study
- •Prior bone marrow or stem cell transplant, or prior radiation to ≥25% of bone marrow (e.g. whole pelvic radiation) for any reason, or any therapeutic radiation within the 3 weeks prior to the XM22 dose
- •Ongoing active infection or history of infectious disease within 2 weeks prior to the screening visit
- •Treatment with lithium at screening or planned during the study.
研究组 & 干预措施
XM22, 100 μg/kg BW
Experimental
干预措施: Lipegfilgrastim (Drug)
结局指标
主要结局
PK: Area under the curve, Maximum observed serum concentration (Cmax), Rate constant associated with terminal phase, Mean Residence Time, Time to reach Cmax, and Apparent volume of distribution during terminal phase after non-intravenous administration
时间窗: 16 months
A total of 7 PK samples will be obtained at prespecified periods
次要结局
- PD:Absolute Neutrophil Count(16 months)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid TumorsNeoplasmsNCT02825940Hoffmann-La Roche120
已完成
1 期
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.Parkinson DiseaseNCT03496870Neurocrine Biosciences16
进行中（未招募）
1 期
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Advanced Solid TumorNCT06421935EMD Serono Research & Development Institute, Inc.60
已完成
1 期
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With HemophiliaHemophilia A With InhibitorHemophilia B With InhibitorHemophilia A Without InhibitorHemophilia B Without InhibitorHemophilia AHemophilia BNCT04072237Catalyst Biosciences11
招募中
1 期
A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) TherapyNon-Muscle-Invasive Bladder Cancer (NMIBC)NCT06351904Ractigen Therapeutics.72